Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Organogenesis Holdings Inc.NASDAQ: ORGO
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt remains negative
Q1 FY2026 short-term debt was $9.72M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +60.2% a year.
Context
- Short-term debt amounted to 1.9% of total assets at the end of Q1 FY2026, up 1.9 pp from a year earlier.
- Short-term debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 18.64M USD
- Year-over-year change
- —
- 4-year CAGR
- +62.8%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.64M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 5.49M | +20.9% |
| FY2022 | 2022-12-31 | 4.54M | +70.9% |
| FY2021 | 2021-12-31 | 2.66M | — |
Short-term Debt vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
- Short-term debt amounts to 1.9% of total assets for ORGO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $82.45M USD | +50.8% | +52.8% | 17.8% | |
| Mar 2026 | CA$34.97M CAD | — | — | 2.7% | |
| Apr 2026 | $23.7M USD | +315.8% | +44.2% | 2.2% | |
| Mar 2026 | $9.72M USD | — | +60.2% | 1.9% | |
| Mar 2026 | $538.23K USD | — | — | 0.2% | |
| Feb 2026 | $0 USD | -100.0% | -64.3% | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ORGO) | — | -24.6% | +44.2% | 0.0% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 113.93M | 102.48M | 104.34M | 135.57M | 93.68M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 82.46M | 89.45M | 82M | 109.86M | 217.45M |
| Inventory | 25.02M | 24.78M | 28.25M | 26.22M | 29.63M |
| Other Current Assets | 711K | 5.1M | 1.19M | 5.67M | 21.43M |
| Total Current Assets | 226.98M | 222.61M | 225.04M | 285.94M | 362.19M |
| Property, Plant & Equipment (Net) | 128.3M | 145.66M | 156.35M | 126.24M | 159.46M |
| Goodwill | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M |
| Intangible Assets | 25.67M | 20.79M | 15.87M | 12.47M | 9.15M |
| Long-term Investments | 0 | 0 | 15.87M | 0 | 0 |
| Tax Assets | 31.99M | 30.01M | 28M | 39.46M | 29.96M |
| Other Non-current Assets | 1.54M | 1.52M | (9.88M) | 5.01M | 9.2M |
| Total Non-current Assets | 216.28M | 226.75M | 234.98M | 211.95M | 236.54M |
| Total Assets | 443.26M | 449.36M | 460.03M | 497.89M | 598.73M |
| Account Payables | 29.34M | 32.33M | 30.72M | 28.91M | 31.95M |
| Short-term Debt | 2.66M | 4.54M | 5.49M | 0 | 18.64M |
| Tax Payables | 1.16M | 2.63M | 2.8M | 4.29M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 29.44M | 9.33M | 22.17M | 25.29M | 49.53M |
| Total Current Liabilities | 82.71M | 75.02M | 80.51M | 77.48M | 100.12M |
| Long-term Debt | 70.77M | 66.23M | 60.75M | 0 | 50.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.56M | 1.12M | 1.21M | 894K | (49.51M) |
| Total Non-current Liabilities | 119.22M | 108.67M | 100.85M | 35.09M | 64.69M |
| Total Liabilities | 201.92M | 183.69M | 181.36M | 112.57M | 164.81M |
| Common Stock | 13K | 13K | 13K | 13K | 13K |
| Retained Earnings | (60.83M) | (45.3M) | (40.97M) | (40.11M) | (3.08M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 241.34M | 265.67M | 278.66M | 385.32M | 433.92M |
| Total Debt | 132.3M | 123.79M | 119.35M | 43.31M | 132.84M |
| Net Debt | 18.37M | 21.31M | 15.01M | (92.26M) | 39.17M |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.